Literature DB >> 17551629

Pilicides-small molecules targeting bacterial virulence.

Veronica Aberg1, Fredrik Almqvist.   

Abstract

In a time of emerging bacterial resistance there is a vital need for new targets and strategies in antibacterial therapy. Using uropathogenic Escherichia coli as a model pathogen we have developed a class of compounds, pilicides, which inhibit the formation of virulence-associated organelles termed pili. The pilicides interfere with a highly conserved bacterial assembly and secretion system called the chaperone-usher pathway, which is abundant in a vast number of Gram-negative pathogens and serves to assemble multi-protein surface fibers (pili/fimbriae). This class of compounds provides a platform to gain insight into important biological processes such as the molecular mechanisms of the chaperone-usher pathway and the sophisticated function of pili. Pili are primarily involved in bacterial adhesion, invasion and persistence to host defenses. On this basis, pilicides can aid the development of new antibacterial agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17551629     DOI: 10.1039/b702397a

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  32 in total

1.  Design and synthesis of C-2 substituted thiazolo and dihydrothiazolo ring-fused 2-pyridones: pilicides with increased antivirulence activity.

Authors:  Erik Chorell; Jerome S Pinkner; Gilles Phan; Sofie Edvinsson; Floris Buelens; Han Remaut; Gabriel Waksman; Scott J Hultgren; Fredrik Almqvist
Journal:  J Med Chem       Date:  2010-08-12       Impact factor: 7.446

2.  Fast uncoiling kinetics of F1C pili expressed by uropathogenic Escherichia coli are revealed on a single pilus level using force-measuring optical tweezers.

Authors:  Mickaël Castelain; Sarah Ehlers; Jeanna Klinth; Stina Lindberg; Magnus Andersson; Bernt Eric Uhlin; Ove Axner
Journal:  Eur Biophys J       Date:  2010-12-16       Impact factor: 1.733

3.  Synthesis and application of a bromomethyl substituted scaffold to be used for efficient optimization of anti-virulence activity.

Authors:  Erik Chorell; Christoffer Bengtsson; Thomas Sainte-Luce Banchelin; Pralay Das; Hanna Uvell; Arun K Sinha; Jerome S Pinkner; Scott J Hultgren; Fredrik Almqvist
Journal:  Eur J Med Chem       Date:  2011-01-21       Impact factor: 6.514

Review 4.  Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs.

Authors:  Hiroshi Ogawara
Journal:  J Antibiot (Tokyo)       Date:  2020-07-09       Impact factor: 2.649

Review 5.  Targeting virulence not viability in the search for future antibacterials.

Authors:  Begoña Heras; Martin J Scanlon; Jennifer L Martin
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

6.  PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice.

Authors:  Y Song; M Baer; R Srinivasan; J Lima; G Yarranton; C Bebbington; S V Lynch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-21       Impact factor: 3.267

Review 7.  Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.

Authors:  Alain L Servin
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

Review 8.  Novel strategies to combat bacterial virulence.

Authors:  Susan V Lynch; Jeanine P Wiener-Kronish
Journal:  Curr Opin Crit Care       Date:  2008-10       Impact factor: 3.687

Review 9.  Structural dissection of the extracellular moieties of the type III secretion apparatus.

Authors:  Yu Wang; Lingling Zhang; Wendy L Picking; William D Picking; Roberto N De Guzman
Journal:  Mol Biosyst       Date:  2008-09-18

10.  Carboxylic acid isosteres improve the activity of ring-fused 2-pyridones that inhibit pilus biogenesis in E. coli.

Authors:  Veronica Berg; Pralay Das; Erik Chorell; Mattias Hedenström; Jerome S Pinkner; Scott J Hultgren; Fredrik Almqvist
Journal:  Bioorg Med Chem Lett       Date:  2008-05-07       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.